The prevalence, incidence, persistence and transmission ways of human papillomavirus infection (HPV)

Česká verze

Authors: B. Sehnal ¹; H. Rozsypal ²; M. Nipčová ¹; J. Sláma ³
Authors place of work: Onkogynekologické centrum, Gynekologicko-porodnická klinika, Nemocnice Na Bulovce a 1. lékařské fakulty Univerzity Karlovy, Praha ¹; Klinika infekčních, parazitárních a tropických nemocí, Nemocnice Na Bulovce a 1. lékařské fakulty Univerzity Karlovy, Praha ²; Onkogynekologické centrum, Gynekologicko-porodnická klinika Všeobecné fakultní nemocnice a 1. lékařské fakulty Univerzity Karlovy, Praha ³
Published in the journal: Epidemiol. Mikrobiol. Imunol. 66, 2017, č. 4, s. 198-209
Category: Souhrnné sdělení

Summary

Human papillomavirus (HPV) is the most common sexually transmitted infection worldwide, which may result in the development of benign or malignant tumours. HPV infec-tions cause approximately 5% of all human cancers. Infection at all sites is strongly associated with sexual behaviour, but this association does not appear to explain substantial differences in the prevalence, incidence, persistence, and clearance of HPV infection in the anal, genital, and oral areas. Discussed are the similarities and differences among the natural histories of infection in different anatomical sites of the human body of both genders. Despite the huge advances already achieved, more research is needed to suggest effective prevention strategies (including the screening of high-risk groups and vaccination) for HPV infection and associated diseases.

Keywords:
human papillomavirus – HPV – prevalence – incidence – persistence – transmission

Zdroje

1. Dyrhonová M, Chlíbek R. Pandemie infekce virem hepatitiy C. Epidemiol Mikrobiol Imunol, 2016;65(2): 72–78.

2. Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine, 2012;30(Suppl 5): F12–23.

3. Ciuffo G. Innesto positivo con filtrato di verruca volgare. Giorn Ital Mal Venereol, 1907; 48: 12–17.

4. Della Torre G, Pilotti S, de Palo G, Rilke F. Viral particles in cervical condylomatous lesions. Tumori, 1978;64: 549–553.

5. Laverty CR, Booth N, Hills E, et al. Noncondylomatous wart virus infection of the postmenopausal cervix. Pathology, 1978;10: 373–378.

6. Muñoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med, 2003;348: 518–527.

7. Vonka V, Kanka J, Hirsch I, et al. Prospective study on the relationship between cervical neoplasia and herpes simplex type-2 virus. II. Herpes simplex type-2 antibody presence in sera taken at enrollment. Int J Cancer, 1984;33(1): 61–66.

8. Tjalma WA, Fiander A, Reich O, et al. Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. Int J Cancer, 2013;132: 854–867.

9. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens – Part B: biological agents. Lancet Oncol, 2009;10(4): 321–322.

10. Kedarisetty S, Orosco RK, Hecht AS, et al. Concordant Oral and Vaginal Human Papillomavirus Infection in the United States. JAMA Otolaryngol Head Neck Surg, 2016; 142(5): 457–465.

11. Termine N, Giovannelli L, Matranga D, et al. Oral human papillomavirus infection in women with cervical HPV infection: new data from an Italian cohort and ameta-analysis of the literature. Oral Oncol, 2011;47(4): 244–250.

12. Du J, Nordfors C, Ahrlund-Richter A, et al. Prevalence of oral human papillomavirus infection among youth, Sweden. Emerg Infect Dis, 2012;18(9): 1468–1471.

13. Steinau M, Hariri S, Gillison ML, et al. Prevalence of cervical and oral human papillomavirus infections among US women. J Infect Dis, 2014;209(11): 1739–1743.

14. Brouwer AF, Eisenberg MC, Carey TE, Meza R. Trends in HPV cervical and seroprevalence and associations between oral and genital infection and serum antibodies in NHANES 2003–2012. BMC Infect Dis, 2015;15: 575.

15. Visalli G, Currò M, Facciolà A, et al. Prevalence of human papillomavirus in saliva of women with HPV genital lesions. Infect Agent Cancer, 2016;11(1): 48.

16. Marques AE, Barra GB, de Resende Oyama CN, et al. Low rate of oropharyngeal human papillomavirus infection of women with cervical lesions and their partners: new data from Brazilian population. J Oral Pathol Med, 2015;44(6): 453–458.

17. Oliveira LH, Santos LS, Silva CO, Augusto EF, Neves FP. Papillomavirus infections in the oral and genital mucosa of asymptomatic women. Braz J Infect Dis, 2017;21: 88–91.

18. Meyer MF, Huebbers CU, Siefer OG, et al. Prevalence and risk factors for oral human papillomavirus infection in 129 women screened for cervical HPV infection. Oral Oncol, 2014;50(1): 27–31.

19. Smith EM, Ritchie JM, et al. HPV prevalence and concordance in the cervix and oral cavity of pregnant women. Infect Dis Obstet Gynecol, 2004;12(2): 45–56.

20. Cañadas MP, Bosch FX, Junquera ML, et al. Concordance of prevalence of human papillomavirus DNA in anogenital and oral infections in a high-risk population. J Clin Microbiol, 2004;42(3): 1330–1332.

21. Carter JJ, Koutsky LA, Hughes JP, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Inf Diseas, 2000;181: 1911–1919.

22. Giuliano AR, Nyitray AG, Kreimer AR, et al. EUROGIN 2014 roadmap: differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection. Int J Cancer, 2015; 136(12): 2752–2760.

23. Safaeian M, Porras C, Schiffman M, et al. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J Natl Cancer Inst, 2010; 102(21): 1653–1662.

24. Lu B, Viscidi RP, Wu Y, et al. Prevalent serum antibody is not a marker of immune protection against acquisition of oncogenic HPV16 in men. Cancer Res, 2012;72: 676–685.

25. Reiter PL, Pendergraft WF, 3rd, Brewer NT. Meta-analysis of human papillomavirus infection concordance. Cancer Epidemiol Biomarkers Prev, 2010;19: 2916–2931.

26. Moscicki AB, Ma Y, Farhat S, et al. Natural history of anal human papillomavirus infection in heterosexual women and risks associated with persistence. Clin Infect Dis, 2014; 58: 804–811.

27. Widdice L, Ma Y, Jonte J, et al. Concordance and transmission of human papillomavirus within heterosexual couples observed over short intervals. J Infect Dis, 2013;207: 1286–1294.

28. Rob F, Tachezy R, Pichlík T, et al. High prevalence of genital HPV infection among long-term monogamous partners of women with cervical dysplasia or genital warts-Another reason for HPV vaccination of boys. Dermatol Ther, 2017;30(1). doi: 10.1111/dth.12435.

29. Hernandez BY, Wilkens LR, Zhu X, et al. Transmission of human papillomavirus in heterosexual couples. Emerg Infect Dis, 2008;14(6): 888–894.

30. Nyitray AG, Lin HY, Fulp WJ, et al. The role of monogamy and duration of heterosexual relationships in human papillomavirus transmission. J Infect Dis, 2014;209: 1007–1015.

31. Parkin DM, Bray F. The burden of HPV-related cancers. Vaccine, 2006;24(Suppl 3): 11–25.

32. Svod.cz. Česky narodni webovy portal epidemiologie nadorů. System pro vizualizaci onkologickych dat. Institut biostatistiky a analyz Lekařske a Přirodovědecke fakulty Masarykovy univerzity (IBA MU). Dostupny na www: http://www.svod.cz.

33. Martel C, Ferlay J, Franceschi S et al. The global burden of cancers attributable to infections in the year 2008: a review and synthetic analysis. Lancet Oncol, 2012;13:607–15.

34. De Vuyst H, Clifford GM, Nascimento MC, et al. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer, 2009;124(7): 1626–1636.

35. Gillison ML, Alemany L, Snijders PJ, et al. Human Papillomavirus and Diseases of the Upper Airway: Head and Neck Cancer and Resipiratory Papillomatosis. Vaccine, 2012;30S: F34–F54.

36. Klozar J, Tachezy R, Rotnáglová E, et al. Human papillomavirus in head and neck tumors: epidemiological, molecular and clinical aspects. Wien Med Wochenschr, 2010;160: 305–309.

37. Näsman A, Attner P, Hammarstedt L, et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer, 2009;125: 362–366.

38. Weinberger PM, Yu Z, Haffty BG, et al. Molecular classification identifies subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol, 2006;24: 736–747.

39. Chaitanya NC, Allam NS, Gandhi Babu DB, et al. Systematic meta-analysis on association of human papilloma virus and oral cancer. J Cancer Res Ther, 2016;12(2): 969–974.

40. Kreimer AR, Clifford GM, Boyle P, et al. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev, 2005;14: 467–475.

41. Kašpírková J, Ondič O, Černá K, Skálová A. Možnosti průkazu biologicky relevantní papilomavirové infekce u maligních nádorů hlavy a krku v diagnostické patologii. Cesk Patol, 2013;49: 29–34.

42. Backes D, Kurman R, Pimenta J, Smith J. Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control, 2009;20: 449–457.

43. Shabbir M, Barod R, Hegarty PK, et al. Primary prevention and vaccination for penile cancer. Ther Adv Urol, 2013;5(3): 161–169.

44. Marty R, Rosse S, Bresse X, et al. Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe. BMC Cancer, 2013;13: 10. doi: 10.1186/1471-2407-13-10.

45. Desai S, Wetten S, Woodhall SC, et al. Genital warts and cost of care in England. Sex Transm Infect, 2011;87: 464–468.

46. Hoy T, Singhal PK, Willey VJ, et al. Assessing incidence and economic burden of genital warts with data from a US commercially insured population. Curr Med Res Opin, 2009; 25: 2343–2351.

47. Kliewer EV, Demers AA, Elliott L, et al. Twenty year trends in the incidence and prevalence of diagnosed anogenital warts in Canada. Sex Transm Dis, 2009;36: 380–386.

48. Marra F, Ogilvie G, Colley L, et al. Epidemiology and costs associated with genital warts in Canada. Sex Transm Infect, 2009;85: 111–115.

49. Insigna RP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis, 2003;361: 397–403.

50. Pirotta M, Stein AN, Conway EL, et al. Genital warts incidence and healthcare resource utilisation in Australia. Sex Transm Infect, 2010;86: 181–186.

51. Monsonego J, Breugelmans JG, Bouee S, et al. Anogenital warts incidence, medical management and costs in women consulting gynaecologists in France. Gynecol Obster Fertil, 2007;35: 107–113.

52. Petráš M, Adámková V. Rates and predictors of genital warts burden in the Czech population. Int J Infect Dis, 2015;35: 29–33.

53. Low AJ, Clayton T, Konate I, et al. Genital warts and infection with human immunodeficiency virus in high-risk women in Burkina Faso: a longitudinal study. BMC Infectious Diseases, 2011;11: 20.

54. Dedo HH, Yu KC. CO(2) laser treatment in 244 patients with resiratory papillomas. Laryngoscope, 2001;111: 1639–1944.

55. Taylor S, Bunge E, Bakker M, Castellsagué X. The incidence, clearance and persistence of non-cervical human papillomavirus infections: a systematic review of the literature. BMC Infect Dis, 2016;16: 293. doi: 10.1186/s12879-016-1633-9.

56. Bruni L, Diaz M, Castellsagué X, et al. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis, 2010;202: 1789–1799.

57. Liu SS, Chan KY, Leung RC, et al. Prevalence and risk factors of Human Papillomavirus (HPV) infection in southern Chinese women – a population-based study. PLoS One, 2011;6(5): e19244. doi: 10.1371/journal.pone.0019244.

58. Zhang R, Shi TY, Ren Y, et al. Risk factors for human papillomavirus infection in Shanghai suburbs: a population-based study with 10,000 women. J Clin Virol, 2013;58(1): 144–148.

59. Ye J, Cheng X, Chen X, et al. Short-term type-specific HPV persistence and its predictors in an asymptomatic general female population in Zhejiang, China. Int J Gynaecol Obstet, 2010;110(3): 217–222.

60. Li LK, Dai M, Clifford GM, et al. Human papillomavirus infection in Shenyang City, People's Republic of China: A population-based study. Br J Cancer, 2006;95(11): 1593–1597.

61. Wu RF, Dai M, Qiao YL, et al. Human papillomavirus infection in women in Shenzhen City, People's Republic of China, a population typical of recent Chinese urbanisation. Int J Cancer, 2007;121(6): 1306–1311.

62. Chen Q, Luo ZY, Lin M, et al. Prevalence and genotype distribution of human papillomavirus infections in women attending hospitals in Chaozhou of Guangdong province. Asian Pac J Cancer Prev, 2012;13(4): 1519–1524.

63. Chui SH, Szeto YT, Lam CW. Human papillomavirus infection in Macau women. Public Health, 2012;126(7): 600–604.

64. de Sanjosé S, Diaz M, Castellsagué X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis, 2007;7(7): 453–459.

65. Guan P, Howell-Jones R, Li N, et al. Human papillomavirus types in 115,789 HPV-positive women: A metaanalysis from cervical infection to cancer. Int J Cancer, 2012;131(10): 2349–2359.

66. Goodman MT, Shvetsov YB, McDuffie K, et al. Acquisition of anal human papillomavirus (HPV) infection in women: the Hawaii HPV Cohort study. J Infect Dis, 2008;197: 957–966.

67. Dunne EF, Nielson CM, Stone KM, et al. Prevalence of HPV infection among men: a systematic review of the literature. J Infect Dis, 2006;194: 1044–1057.

68. Hebnes JB, Olesen TB, Duun-Henriksen AK, et al. Prevalence of genital human papillomavirus among men in Europe: systematic review and meta-analysis. J Sex Med, 2014;11: 2630–2644.

69. Profozić Z, Meštrović T, Savić I, et al. Prevalence of HPV Infection in Croatian Men during a 12-year Period: a Comparative Study of External Genital and Urethral Swabs. Cent Eur J Public Health, 2016;24(4): 321–325.

70. Tobian AAR, Kigozi G, Gravitt PE, et al. Human papillomavirus incidence and clearance among HIV-positive and HIV-negative men in sub-Saharan Africa. AIDS, 2012;26: 1555–1565.

71. Giuliano AR, Lee JH, Fulp W et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet, 2011; 377(9769): 932–940.

72. Machalek DA, Poynten M, Jin F, et al. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol, 2012;13: 487–500.

73. Silverberg MJ, Lau B, Justice AC, et al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Diseases, 2012;54: 1026–1034.

74. Goodman MT, Shvetsov YB, McDuffie K, et al. Sequential acquisition of human papillomavirus (HPV) infection of the anus and cervix: the Hawaii HPV Cohort Study. J Infect Dis, 2010;201(9): 1331–1339.

75. Shvetsov YB, Hernandez BY, McDuffie K, et al. Duration and clearance of anal human papillomavirus (HPV) infection among women: the Hawaii HPV cohort study. Clin Infect Dis, 2009;48: 536–546.

76. Mullins TLK, Wilson CM, Rudy BJ, et al. Incident anal human papillomavirus and human papillomavirus-related sequelae in HIV-infected versus HIV-uninfected adolescents in the United States. Sex Transm Dis, 2013;40: 715–720.

77. Slama J, Sehnal B, Dusek L, et al. Impact of risk factors on prevalence of anal HPV infection in women with simultaneous cervical lesion. Neoplasma, 2015;62(2): 308–314.

78. Nyitray AG, da Silva RJ C, Baggio ML, et al. Six-month incidence, persistence, and factors associated with persistence of anal human papillomavirus in men: the HPV in men study. J Infect Dis, 2011;204: 1711–1722.

79. Kreimer AR, Bhatia RK, Messeguer AL, et al. Oral human papillomavirus in healthy individuals: a systematic review of the literature. Sex Transm Dis, 2010;37(6): 386–391.

80. Gillison ML, Broutian T, Pickard RK, et al. Prevalence of oral HPV infection in the United States, 2009–2010. Jr Am Med Assoc, 2012;307: 693–703.

81. Pickard RK, Xiao W, Broutian TR, et al. The prevalence and incidence of oral human papillomavirus infection among young men and women, aged 18–30 years. Sex Transm Dis, 2012;39: 559–566.

82. Beachler DC, D’Souza G, Sugar EA, et al. Natural history of anal vs oral HPV infection in HIV infected men and women. J Infect Dis, 2013;208: 330–339.

83. Louvanto K, Rautava J, Syrjänen K, et al. The clearance of oral high-risk human papillomavirus infection is impaired by long-term persistence of cervical human papillomavirus infection. Clin Microbiol Infect, 2014;20(11): 1167–1172.

84. Rintala M, Grénman S, Puranen M, et al. Natural history of oral papillomavirus infections in spouses: a prospective Finnish HPV Family Study. J Clin Virol, 2006;35: 89–94.

85. Scholefield JH, Sonnex C, Talbot IC, et al. Anal and cervical intraepithelial neoplasia: possible parallel. Lancet, 1989;2: 765–769.

86. Hernandez BY, McDuffie K, Zhu X, et al. Anal Human Papillomavirus Infection in Women and Its Relationship with Cervical Infection. Cancer Epidemiol Biomarkers Prev, 2005;14(11): 2550–2556.

87. Castro FA, Quint W, Gonzalez P, et al. Prevalence of and risk factors for anal human papillomavirus infection among young healthy women in Costa Rica. J Infect Dis, 2012;206: 1103–1110.

88. Giuliano AR, Lazcano-Ponce E, Villa LL, et al. The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States. Cancer Epidemiol Biomarkers Prev, 2008;17: 2036–2043.

89. Hemminki K, Dong C, Frisch M. Tonsillar and other upper aerodigestive tract cancers among cervical cancer patients and their husbands. Eur J Cancer Prev, 2000;9(6): 433–437.

90. Chaturvedi AK, Kleinerman RA, Hildesheim A, et al. Second cancers after squamous cell carcinoma and adenocarcinoma of the cervix. J Clin Oncol, 2009;27(6): 967–973.